![Seng Chin Mah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Posizioni attive di Seng Chin Mah
Società | Posizione | Inizio | Fine |
---|---|---|---|
BioVersys AG
![]() BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Presidente | - | - |
Storia della carriera di Seng Chin Mah
Precedenti posizioni note di Seng Chin Mah
Società | Posizione | Inizio | Fine |
---|---|---|---|
Canyon Pharmaceuticals, Inc.
![]() Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD. | Amministratore Delegato | - | - |
Presidente | 03/08/2009 | - |
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Svizzera | 2 |
Posizioni
Chairman | 2 |
Chief Executive Officer | 1 |
Settori
Health Technology | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Canyon Pharmaceuticals, Inc.
![]() Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD. | Health Technology |
BioVersys AG
![]() BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
- Borsa valori
- Insiders
- Seng Chin Mah
- Esperienza